In a significant stride against cholera outbreaks, the World Health Organisation (WHO) has announced the prequalification of a groundbreaking oral vaccine, Euvichol-S.
The WHO’s press statement, released on Thursday, revealed that the prequalification was granted on April 12, 2024, marking a pivotal moment in global healthcare.
The prequalification process, a hallmark of WHO’s rigorous standards, ensures that vaccines meet international safety and efficacy benchmarks. Euvichol-S, developed through a collaborative effort between EuBiologics, the International Vaccine Institute, and the Bill and Melinda Gates Foundation, promises a simplified formulation without compromising efficacy.
This breakthrough offers opportunities for rapid scalability in production to meet the pressing demand amidst cholera outbreaks.
Dr. Rogerio Gaspar, Director of the WHO Department for Regulation and Prequalification, emphasised the urgent need for increased production and supply to aid communities grappling with cholera outbreaks globally.
Cholera, an endemic and seasonal scourge, particularly affects regions with inadequate sanitation, like Nigeria. The alarming surge in cholera cases, with 473,000 reported to WHO in 2022 and an estimated increase of 700,000 in 2023, underscores the critical need for effective interventions.
Gavi, the Vaccine Alliance, and the United Nations Children’s Fund (UNICEF) have hailed the prequalification of Euvichol-S as a game-changer. This milestone paves the way for expanded production capacity, enabling swift response to cholera outbreaks worldwide.
Furthermore, WHO’s initiative to distribute over 1.2 million cholera diagnostic tests to 14 high-risk countries underscores the comprehensive approach to combating this deadly disease. Dr. Derrick Sim of Gavi emphasised the significance of timely vaccine deployment amid the acute upsurge of cholera outbreaks.
The approval of Euvichol-S not only signifies a lifeline for vulnerable communities but also demonstrates concerted efforts to shape the cholera vaccine market for equitable access. UNICEF’s commitment to expedited procurement and delivery ensures that affected countries receive the much-needed vaccine doses promptly.
Despite the preventable and treatable nature of cholera, children remain at risk. UNICEF’s swift action in securing access to the newly approved vaccine underscores the determination to mitigate the impact of cholera outbreaks and protect vulnerable populations worldwide.
As the global fight against cholera intensifies, the prequalification of Euvichol-S marks a significant leap forward in safeguarding public health and advancing global immunization efforts.
